World’s First Next-Generation Protein Sequencing Device to Accelerate the Study of Diseases and Pandemics

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Protein Sequencing Device: Over the past fifteen years, next-generation DNA sequencing has transformed every aspect of the life sciences. However, genetics is only one component of human disease. New tools are required to understand how genes interact with the environment to improve how we develop drugs, diagnose patients, and combat outbreaks. Protein-based approaches have always held tremendous promise, but despite massive improvements in DNA sequencing technology, proteomics (the study of proteins on a large scale) has not advanced as rapidly.

“Prior to our team commercializing the first next-generation DNA sequencing system, scientists relied on noisy analog data generated by DNA-hybridization,” said Jonathan M. Rothberg, Ph.D., Founder and Chairman of Quantum-Si. “By advancing to a digital readout in the actual sequencing of DNA in a genome, we unlocked new areas of biology and created what researchers and doctors identified as the greatest advance in healthcare in the last 40 years. Next-generation protein sequencing will be as important and will have an even greater economic impact.”

Sample to Answer Solutions: To maximize the impact on global health, the world needs true end-to-end solutions that are convenient, fast, and affordable. Quantum-Si introduced a complete solution spanning sample preparation, protein sequencing, and data analysis.

Platinum is the first of Quantum-Si’s devices to utilize Time Domain Sequencing™ powered by the world’s first massively parallel single-photon counting semiconductor chip. “Our chip is universal and can be applied to research complex disease, as well as the most exquisite early detection of pathogens, as with the Coronavirus pandemic,” said Dr. Rothberg. With this $100 million dollar development, Quantum-Si is able to drastically reduce the cost and size of sequencing platforms and create next-generation protein sequencing. Quantum-Si’s chip allows a user to read the amino acid sequence (the building blocks of proteins) and post-translational modifications. For the very first time, Platinum allows any lab or clinic to sequence proteins in an affordable, easy-to-use, and massively parallel fashion.

Carbon is designed as a universal sample preparation platform to automate the upfront work needed for sequencing. In addition to automating protein preparation for Platinum, Carbon also automates sample preparation from whole-blood and cell cultures for existing third-party DNA sequencing technologies.

The Quantum-Si Cloud provides a secure platform for users to manage samples, libraries, runs, and analyses. The Cloud also enables developers to test and run custom workflows, then share the workflows with the broader community if desired.

Quantum-Si’s end-to-end solution is designed to create a new proteomics market and usher in the age of protein sequencing, but the company has a larger vision. “The ability to detect light is central to modern diagnostics. There are additional markets and applications where our single-molecule sensor and ecosystem of products can be applied, “said Dr. Rothberg. “We are just getting started.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.